Publications – KalVista Pharmaceuticals

Showing 4 out of 4

Relationship Between PGI-C Scale and Other PROs in KVD900 Trial in Hereditary Angioedema

Audhya P, Williams P, Yea CM

ACAAI 2021

A single on-demand treatment with orally administered KVD900 significantly slows progression and accelerates resolution of attacks in patients with hereditary angioedema (HAE): Results of a phase 2, placebo-controlled, double-blind cross-over trial

Aygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Cancian M, Hakl R, Kinaciyan T, Magerl M, Martinez-Saguer I, Stobiecki M, Grivcheva-Panovska V, Kiani-Alikhan S, Krcmova I, Bernstein J, Manning M, Stroud C, Hanzlikova J, Li HH, Longhurst HJ, Melamed IR, Young P, Feener E, Iverson M, Maetzel A, Morten RM, Smith MD, Watissée MI, Williams P, Yea CM, Maurer M, Banerji A, and Riedl MA

EAACI 2021

On-demand Oral Treatment With KVD900 for HAE Attacks Achieves Rapid Exposure and Improves Patient Outcomes

Bernstein JA, Huamin LH, Yea CM, Maetzel A, Audhya P, Williams P, Banerji A, Riedl MA

ACAAI 2021

Fast improvement of hereditary angioedema (HAE) attacks with the oral on-demand plasma kallikrein inhibitor KVD900: an analysis of the pharmacokinetic and pharmacodynamic profile of KVD900 and attack symptom severity during a double-blind, randomized phase 2 cross-over trial in patients with HAE type I and II

Zanichelli, Andrea
C1-INHIBITOR WORKSHOP 2021

About

Science

Pipeline

Careers

Contact